Search

Simulation is a technique where the situation or a process is imitated. This process makes one to pretend the scenario. Aviation industry is one of the oldest industry which uses simulation technique to simulate the aviation technique. The main aim of having simulation lab is to make students acquire psychomotor skills before they actually treat the patients. Presently the National Medical Council of India has made it mandatory to have a skill lab but desirable to have a simulated mannequin for the training of medical students before actually treating the patients. Various advantages and disadvantages are appreciated in simulation technique. It is not very far that Dental council of India may make compulsory training of certain simulated modules in dentistry before treating the patient. Simulation lab in the pandemic like COVID has really helped people to undergo extensive training before treating patients, especially one who were catering the COVID ward or intensive care units. The simulation in dentistry is not a very old technique, certain technique are already in practice, but this article tries to highlight the necessity and gray areas where simulation can be improved for the benefit of students to learn and for the benefit of patients in view of safety.

The aim of the present study is to evaluate the clinical efficacy of Azadirachta Indica (A. Indica)/ neem mouth rinse in conjunction with scaling and root planning in the treatment of chronic gingivitis and chronic periodontitis. Total of 50 patients who were diagnosed with generalized chronic gingivitis and chronic periodontitis were divided equally into 2 groups. In first group subgingival ultrasonic instrumentation was performed along with the 0.2% chlorhexidine mouth rinse and in the other group 10% A. indica-mouth rinse was used. Clinical parameters were recorded on the baseline, 7thday, 30th day and 90th-day post-therapy. The intra-group comparison showed a statistically significant difference in clinical parameters at different intervals post-therapy whereas in the inter-group comparison the difference in clinical parameters was statistically non-significant at various time intervals. Neem mouthwash as an irrigant during ultrasonic scaling enhances the benefits of scaling and root planing in the treatment of chronic gingivitis and chronic periodontitis and can be used as an effective alternative for chlorhexidine.

8019 Background: Preclinical data demonstrate that nirogacestat, a gamma-secretase inhibitor, may increase cell-surface levels of a B-cell maturation antigen (BCMA) and reduce soluble BCMA levels, which could enhance anti-BCMA agent activity in multiple myeloma. In the DREAMM-5 (NCT04126200) Phase I/II platform trial belantamab mafodotin (belamaf; BLENREP), a BCMA-targeting antibody-drug conjugate, is being evaluated in combination with nirogacestat to determine if the combination can result in similar efficacy and an improved ocular safety profile compared to the currently approved belamaf schedule (single agent dose 2.5 mg/kg Q3W) in patients with RRMM which showed a 31% overall response rate (ORR) and 44.5% Gr3/4 keratopathy (BLENREP US prescribing information). Methods: This cohort within the DREAMM-5 nirogacestat combination sub-study has a sequential dose-exploration (DE) phase evaluating 0.95 mg/kg Q3W belamaf with 100 mg BID nirogacestat continuously, followed by a randomized cohort expansion (CE) comparing the combination to a belamaf 2.5 mg/kg Q3W arm. Results: Preliminary results from the 10 patients (pts) in the DE cohort with low-dose belamaf + nirogacestat are presented in this abstract. Pts had a median (range) of 4.5 (3–10) prior lines of therapy. At time of data cut-off (Nov 15, 2021), pts received a median (range) of 7 cycles (1–26). The ORR was 60% (n=6/10) and 20% (n=2) achieved a very good partial response (Table). The key emergent adverse events (AEs) included ocular events (n=7 [70%]; ≥Grade [Gr] 3, n=2 [20%] of which Gr 3 keratopathy was reported in 1 pt [10%]), diarrhea (n=7 [70%]; Gr 3, n=1 [10%]) and hypophosphatemia (n=7 [70%]; Gr 3, n=1, [10%]). There were 2 Grade 5 AEs, neither of which were related to study treatment. No pt permanently discontinued study due to treatment related AEs. Conclusions: Encouraging clinical activity and a manageable safety profile is observed with low dose belamaf (0.95 mg/kg Q3W) + nirogacestat (100 mg BID continuously) in pts with RRMM. This ongoing sub-study is actively recruiting patients and will continue to evaluate belamaf + nirogacestat efficacy and safety. Updated results will be reported at the congress. Funding: GSK (208887); drug linker technology licensed from Seagen Inc.; mAb produced using POTELLIGENT Technology licensed from BioWa. Clinical trial information: NCT04126200. [Table: see text]